COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (INTASAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01174186
Recruitment Status : Completed
First Posted : August 3, 2010
Results First Posted : November 17, 2014
Last Update Posted : December 2, 2014
Medtronic - MITG
Central Denmark Region
Information provided by (Responsible Party):
Rene Oestgaard, Regionshospitalet Silkeborg

Brief Summary:
Studies with intestinally asymptomatic patients with spondyloarthritis showed that approximately 1/3 had visible ulcers in the colon by scopic examinations and 2/3 had changes detectable by microscopy. Only those patients who improved in arthritis symptoms showed improvement in colonic changes. In these studies only colon and the terminal ileum was examined. Inflammation of the small intestine was not examined. Newer studies have shown an immunological link between Crohns disease and spondyloarthritis but not ulcerative colitis. The investigators wish to examine the small intestine in these patients before and after treatment, since they expect to find ulcers there linking spondyloarthritis to Crohns disease and healing after treatment.

Condition or disease Intervention/treatment Phase
Spondyloarthritis Enterocolitis Drug: Adalimumab Phase 4

Detailed Description:

Patients with inflammatory axial spondyloarthritis according to the assessment group in ankylosing spondylitis (ASAS) criteria (8) and active disease assessed by a physician are recruited in the outpatient clinics of the rheumatology departments, provided that the patient under normal circumstances is expected to benefit from TNF-alpha inhibitor treatment and full fill the criteria for treatment. Screening with a view to participating in the study is carried out in accordance with the inclusion and exclusion criteria. Oral and written patient information about the study, the patient's signing of the informed consent form and the signing of the patient's power of attorney in accordance with the study protocol are also a condition for the inclusion. The including physician will ensure that a potential participant is informed about the right to at least 1 hour's reflection time and the right to have a friend/family member present at the information interview.

If the patient meets the basis for the participation in the study the informed consent form and the power of attorney are signed.

The screened patients are not coded but are identified using their Civil Registration Number (CPR) for several reasons. The study is open-label, which removes the need for blinding of patients as well as investigator. Blood samples are booked electronically and printed labels with CPR number are put on the test tubes for both immediate analysis and storage. This guarantees a more fail-safe method for handling of various analyses, since this procedure is similar to the routine procedure. We find this to be the safest system as the method, by which labels with CPR number follow the patient has been thoroughly tested.

Source data will be kept in the Danish Biologics Online Registry (DANBIO registry) for clinical measures, the electronic patient file for lab data and the paper file for imaging data. Data validity and completeness is controlled by external "good clinical practice" monitoring.

Adalimumab will be supplied as a sterile solution without preservatives for subcutaneous injection in 1 ml prefilled syringes containing adalimumab 40 mg/0.8 ml, to be self-injected by the patient every 2 weeks until week 20. After week 20 patients continue adalimumab treatment 40 mg every other week but may change to injections with pens containing the same drug and dosage. The drug is injected under the skin of the abdomen or the thigh. All patients will be instructed by the study personnel in correct sterile subcutaneous injection of the study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing
Study Start Date : October 2010
Actual Primary Completion Date : June 2013
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Arm Intervention/treatment
Active Comparator: Spondyloarthritis and calprotectin elevated
Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
Drug: Adalimumab
Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Other Name: Humira

Active Comparator: Spondyloarthritis and calprotectin normal
Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
Drug: Adalimumab
Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Other Name: Humira

Primary Outcome Measures :
  1. Change Lewis Score Index [ Time Frame: 20 weeks ]

    Lewis' score describes the amount of inflammation seen optically by capsular endoscopy.

    Gralnek et al. devised and validated the Lewis score index, based on three endoscopic parameters: villous edema, ulcer and stenosis/stricture. Using these parameters, the authors established a score range of 8-4,800 points where: LS < 135 reflects normal mucosal appearances, LS 135-790 mild mucosal inflammatory change and an LS value ≥790 moderate to severe mucosal inflammatory changes.

    The patients had endoscopy performed at baseline and again after 20 weeks. The number of patients improving was compared to number of patients deteriorating

  2. Change in Intestinal Inflammation Measured by Faecal Calprotectin [ Time Frame: Baseline to 52 weeks ]

    Feacal calprotectin is a protein and a marker of the degree of inflammation in the intestine, but not the site of inflammation.

    We measured the level calprotectin continuously in each of the patients. Difference was inferred by repeated measurement ANOVA

Secondary Outcome Measures :
  1. Spondyloarthritis Consortium of Canada Score [ Time Frame: one year ]
    Inflammation on MRI assessed by the Spondyloarthritis Consortium of Canada score and a Danish scoring method

  2. Assessment Group in Ankylosing Spondylitis (ASAS) Core Set for Clinical Practice [ Time Frame: one year ]
    clinical measurements of inflammation in spondyloarthritis patients as described by the Assessment Group in Ankylosing Spondylitis (ASAS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients (18 years and ≤45 years) with axial SpA according to the ASAS criteria
  • Active SpA assessed by physician.
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4.
  • Faecal calprotectin ≥ 100mg/kg.
  • Negative pregnancy test (serum-HCG) for women of childbearing age before the start of the study. (Women not of childbearing age are defined as postmenopausal for at least 1 year or surgically sterilised (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)). Women of childbearing age included in the study will be required to use contraception during the entire study period (i.e. one of the following: contraceptive pills, intrauterine device, depot injection of gestagen, subdermal implant, hormonal vaginal ring or transdermal patch). In addition, contraception must be used following any discontinuation of the study drug for a period of 150 days.
  • Ability and willingness to self-administer the subcutaneous injections or have a person available to administer the injections.
  • Ability and willingness to give written informed consent and meet the requirements of the study protocol.

Exclusion Criteria:

  • Diagnosed inflammatory bowel disease or high risk of intestinal stricture (previous abdominal stricture, radiation of abdomen, major abdominal surgery).
  • Non steroid anti inflammatory Drugs (NSAID) ingestion less than 4 weeks before inclusion.
  • Psoriasis
  • Persons with latent Tuberculosis (TB)(positive Mantoux skin test (>10 mm), positive cultivation for mycobacteria in tissue samples and/or chest X-ray indicating TB) or other risk factors for activation of untreated latent TB.
  • Current or recurrent infections or serious infections requiring hospitalisation or treatment with intravenous antibiotics within the last 30 days or oral antibiotics within the last 14 days before inclusion.
  • Positive serology for Hepatitis B or C indicating active infection.
  • Medical history of positive HIV status (in case of suspicion control of HIV test).
  • Medical history of histoplasmosis or listeriosis.
  • Previous cancer or lymphoid proliferative disease except completely well-treated cutaneous squamous cell carcinoma, basal cell carcinoma or cervical dysplasia.
  • Previous diagnosis or signs of demyelinising diseases of the central nervous system (e.g. optic neuritis, disturbance of vision, disturbed gait/ataxia, facial paresis, apraxia).
  • Severe renal insufficiency (creatinine clearance < 35 ml/min - normogram).Affected hepatic function: Liver enzymes > 3 x above the normal limit.
  • Clinically significant drug or alcohol abuse in the last year or daily current alcohol consumption.
  • Diabetes, unstable ischemic heart disease, heart failure (NYHA III-IV), recent apoplexia cerebri (within 3 months), chronic leg ulcer and any other condition (e.g. indwelling catheter) which at the discretion of the investigator means that participation in the protocol would entail a risk for the person in question.
  • Anticoagulant treatment.
  • Pregnancy or breast-feeding.
  • Other clinically significant inflammatory rheumatologic diseases that cannot be related to spondyloarthritis
  • Current parvovirus B 19 infection.
  • Glucocorticosteroid treatment within the last 4 weeks (except nasal and inhalation steroids).
  • Contraindication to study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01174186

Layout table for location information
Department of Rheumatology U, Aarhus Hospital
Aarhus, Denmark, 8000
Regional Hospital of Horsens, Department of Medicine
Horsens, Denmark, 8700
Regional Hospital of Randers, Department of Medicine
Randers, Denmark
Regional Hospital of Silkeborg
Silkeborg, Denmark, 8600
Sponsors and Collaborators
Regionshospitalet Silkeborg
Medtronic - MITG
Central Denmark Region
Layout table for investigator information
Study Chair: Henning Glerup, M.D. Regional Hospital Silkeborg, medical department
Study Director: René D Oestgaard, M.D. Regional Hospital Silkeborg, medical department
Principal Investigator: Bent Deleuran, M.D. Department of Medical Microbiology and Immunology Aarhus University
Layout table for additonal information
Responsible Party: Rene Oestgaard, René Østgård, MD, Regional Hospital Denmark, medical department, Regionshospitalet Silkeborg Identifier: NCT01174186    
Other Study ID Numbers: 4682724
First Posted: August 3, 2010    Key Record Dates
Results First Posted: November 17, 2014
Last Update Posted: December 2, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis, Ankylosing
Pathologic Processes
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Anti-Inflammatory Agents
Antirheumatic Agents